← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.91 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.90 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89 Optimized Temporal Window for Metabolic Boosting Therapy Det (IFNG) — 0.89 TREM2-APOE Axis Dissociation for Selective DAM Activation (TREM2-APOE axis) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.88 APOE-Dependent Autophagy Restoration (MTOR) — 0.88 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.87 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.87 Complement Cascade Inhibition Synaptic Protection (%s) — 0.87 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.87 Optogenetic restoration of hippocampal gamma oscillations vi (PVALB) — 0.87 Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated (PVALB, CREB1, lncRNA-9969, neuronal autophagy pathway) — 0.87 Glymphatic-Mediated Tau Clearance Dysfunction (MAPT) — 0.86 Closed-loop focused ultrasound targeting EC-II PV interneuro (PVALB) — 0.86 TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima (NAMPT) — 0.86 TREM2-Mediated Microglial Dysfunction Disrupts Perivascular (TREM2) — 0.86 Circadian Glymphatic Entrainment via Targeted Orexin Recepto (HCRTR1/HCRTR2) — 0.86 RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P (RBM45,GSK3B,TDP-43,TARDBP,hnRNP A1,HNRNPA1,phase separation,Liquid droplet) — 0.86
Add
|
× METTL3-Mediated m6A Modif × Plasma p-tau217-Triggered
METTL3, YTHDF2, lncRNA-0021 (m6A-modified) · molecular neurobiology · -
Composite 0.759
Price $0.70
Evidence For 0
Evidence Against 0
## **Molecular Mechanism and Rationale**
The methyltransferase-like 3 (METTL3) enzyme functions as the catalytic subunit of the m6A methyltransferase complex, working in conjunction with METTL14 and WTAP to deposit N6-methyladenosine modifications on adenosine residues within specific RNA sequences. In the context of lncRNA-0021, METTL3 catalyzes the methylation of adenosine residues at positions 180-220, creating a critical m6A modification landscape that governs the long non-coding RNA's tert
CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes · molecular neurobiology · -
Composite 0.323
Price $0.39
Evidence For 0
Evidence Against 0
## Mechanistic Overview
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD starts from the claim that modulating CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes within the disease context of molecular neurobiology can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The therapeutic hypothesis centers on the precise temporal coordination between plasma phosphorylated tau-217 (p-tau217) biomarke
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
Neuroinflammation Protein Aggregation molecular neurobiology
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary 10/11
dimensions won
METTL3-Mediated m6A Modification of lncR
1/11
dimensions won
Plasma p-tau217-Triggered Exosome Dosing
Radar Chart — 10 Dimensions
Score Breakdown
Dimension METTL3-Mediated m6A Modificati Plasma p-tau217-Triggered Exos Mechanistic 0.450 0.300 Evidence 0.350 0.150 Novelty 0.650 0.800 Feasibility 0.350 0.120 Impact 0.500 0.250 Druggability 0.550 0.100 Safety 0.350 0.200 Competition 0.650 0.400 Data 0.300 0.100 Reproducible 0.350 0.050 KG Connect 0.662 0.538
Evidence METTL3-Mediated m6A Modification of lncRNA-0021 Regulates mi No evidence citations yet
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 No evidence citations yet
Price History Overlay